CG Invites Co., Ltd. (KOSDAQ:083790)

South Korea · Delayed Price · Currency is KRW

1,002.00

-4.00 (-0.40%)

Jul 1, 2026, 9:19 AM KST

-45.07% (1Y)

Market Cap	77.36B -50.0%
Revenue (ttm)	29.22B +224.6%
Net Income	-3.23B
EPS	-43.07
Shares Out	76.89M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,764
Open	1,006.00
Previous Close	1,006.00
Day's Range	987.00 - 1,006.00
52-Week Range	760.00 - 1,985.00
Beta	-0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About CG Invites

CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The compan... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2000

Employees 73

Stock Exchange KOSDAQ

Ticker Symbol 083790

Full Company Profile

Financial Performance

In 2025, CG Invites's revenue was 27.39 billion, an increase of 277.64% compared to the previous year's 7.25 billion. Losses were -3.52 billion, -93.17% less than in 2024.

Financial Statements